Plasma fibrinogen associates independently with total and cardiovascular mortality among subjects with normal and reduced kidney function in the general population

1.04–1.09] for total mortality and 1.06 (95% CI 1.03–1.09) for cardiovascular mortality. The adjusted HR for total mortality was 1.05 (1.01–1.09) for subjects with eGFR 60–90 ml/min/1.73 m 2 and 1.06 (1.02–1.10) for subjects with eGFR 90, 60–90 and <60 ml/min/1.73 m 2 experienced HRs of 1.45 (95% CI 1.03–2.03), 1.35 (95% CI 1.00–1.83) and 1.72 (95% CI 1.14–2.58), respectively, compared with subjects in the lowest quartile group. The patterns were similar for cardiovascular mortality. Conclusions: Plasma fibrinogen associates with mortality among subjects with mild to moderate kidney impairment as it does in subjects with normal kidney function and should be considered a therapeutic target for cardiovascular risk reduction.